Indoor Biotechnologies Expansion In India
Friday, January 30, 2015
InBio India will distribute all of Indoor Biotechnologies products in India under the direction of Dr. Shivshankar Baalasubramanian (Shiv).
The InBio India opportunity will impact the allergy/immunology field. Based on a recent study of IgE antibody prevalence with over 20,000 subjects suggests that allergy is a significant health problem, affecting 1 in 7 of the Indian population.
Shiv joins InBio from academia, having a PhD in Immunology from AIIMS, New Delhi and having worked on T cell biology, complement biology, autoimmunity and tumor immunobiology at the Cardiff University School of Medicine, Wales, UK. Shiv also spent four years as Principal Investigator within the Infection and Immunity program at the Singapore Institute for Clinical Sciences, before returning to Bangalore in 2013.
InBio India will distribute all of Indoor Biotechnologies products in India, including purified allergens, ELISA and MARIA® kits, Ventia™ and DUSTREAM® devices for environmental sampling. InBio India will have a fully equipped laboratory to provide allergen exposure testing using the exclusive ELISA and MARIA® technology.
This will be one of the first labs in India to provide commercial testing services on the Luminex xMAP® system. A key objective of InBio India will be to expand the scope of services provided to encompass a broad range of Luminex testing, immunology services and contract research for the rapidly growing pharmaceutical and biotechnology sector in India. InBio India's lab will be operational in April 2015.